Therapy of Myelodysplastic Syndrome (MDS) with azacitidine given in combination with etanercept: A phase II study

被引：0
|
作者：
Holsinger, Aaron L. [1 ,2 ]
Ramakrishnan, Aravind [1 ,2 ]
Storer, Barry [1 ,2 ]
Becker, Pamela S. [1 ,2 ]
Petersdorf, Stephen [1 ,2 ]
Deeig, H. Joachim [1 ,2 ]
Scott, Bart L. [1 ,2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1452
引用
收藏
页码：435A / 435A
页数：1
相关论文
共 50 条
  • [21] Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Cortes, Jorge E.
    Borthakur, Gautam
    DiNardo, Courtney D.
    Daver, Naval G.
    Jain, Nitin
    Naqvi, Kiran
    Jabbour, Elias J.
    Sheppard, Kimberly B.
    Pierce, Sherry A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2018, 132
  • [22] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
    Kenealy, Melita K.
    Seymour, John F.
    Linda, Cowan
    Milner, Alvin
    Giri, Pratyush
    Ho, Shir-Jing
    Benson, Warwick
    Nicol, Andrew
    Campbell, Philip
    Prosser, Ian
    Underhill, Craig
    Cunningham, Ilona
    Mills, Anthony K.
    Szer, Jeffrey
    Presgrave, Peter
    Filshie, Robin
    BLOOD, 2009, 114 (22) : 695 - 695
  • [23] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [24] COMBINATION OF ORAL RIGOSERTIB AND INJECTABLE AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Fenaux, P.
    Petrone, M.
    Zbyszewski, P.
    Fruchtman, S.
    Silverman, L.
    LEUKEMIA RESEARCH, 2017, 55 : S30 - S30
  • [25] Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With Azacitidine in Advanced Myelodysplastic Syndrome
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)
  • [26] Azacitidine in Combination With Venetoclax for Myelodysplastic Syndrome (MDS) With Increased Blasts-2 in Clinical Practice Setting
    Davainiene, Birute
    Cepulyte, Ruta
    Trociukas, Igoris
    Pileckyte, Regina
    Griskevicius, Laimonas
    Zucenka, Andrius
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S287 - S287
  • [27] Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higherrisk myelodysplastic syndrome (MDS).
    Desikan, Sai Prasad
    Montalban-Bravo, Guillermo
    Ohanian, Maro
    Daver, Naval Guastad
    Kadia, Tapan M.
    Venugopal, Sangeetha
    Chien, Kelly Sharon
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Profile: Final Results of the Valena Trial
    Kuendgen, Andrea
    Luebert, Michael
    Schlenk, Richard F.
    Platzbecker, Uwe
    Haase, Detlef
    Haferlach, Torsten
    Schnittger, Susanne
    Giagounidis, Aristoteles
    Brings, Carolin
    Germing, Ulrich
    Haas, Rainer
    Gattermann, Norbert
    BLOOD, 2014, 124 (21)
  • [29] Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy.
    Borthakur, Gautam
    Ravandi-Kashani, Farhad
    Cortes, Jorge
    Jabbour, Elias
    Faderl, Stefan
    O'Brien, Susan
    Verstovsek, Srdan
    Garcia-Manero, Guillenno
    Newman, Beth Ann
    Giles, Francis
    Issa, Jean-Pierre
    Kantarjian, Hagop M.
    BLOOD, 2006, 108 (11) : 157A - 157A
  • [30] Results of phase II clinical study of lenalidomide in Japanese patients with myelodysplastic syndrome (MDS)
    Harada, H.
    Watanabe, M.
    Suzuki, K.
    Yanagita, S.
    Suzuki, T.
    Yoshida, Y.
    Kimura, A.
    Tsudo, M.
    Takatoku, M.
    Ozawa, K.
    LEUKEMIA RESEARCH, 2009, 33 : S123 - S123
12345